Dr. Gordon Downey, Chief Medical Officer at CyPath, hosting a panel discussion with three expert pulmonologists about CyPath Lung Testing as a diagnostic tool for pulmonary nodule assessment.
A panel of pulmonologists discuss their use of CyPath® Lung in clinical practice as part of a comprehensive approach to lung cancer risk assessment, pulmonary nodule management, and surveillance of lung cancer survivors post-treatment. A key theme that emerges from the conversation is how CyPath® Lung enhances clinical confidence in determining appropriate next steps for patients at risk for lung cancer.
A panel of pulmonologists discuss their use of CyPath® Lung in clinical practice as part of a comprehensive approach to lung cancer risk assessment, pulmonary nodule management, and surveillance of lung cancer survivors post-treatment. A key theme that emerges from the conversation is how CyPath® Lung enhances clinical confidence in determining appropriate next steps for patients at risk for lung cancer.
